NASDAQ:DOMH Dominari 11/6/2023 Earnings Report $3.64 +0.35 (+10.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.75 +0.11 (+2.91%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dominari EPS ResultsActual EPS-$0.66Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADominari Revenue ResultsActual Revenue$0.96 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADominari Announcement DetailsQuarterDate11/6/2023TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsDominari's next earnings date is estimated for Wednesday, May 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Dominari Earnings HeadlinesDominari Holdings Announces Record Date for Cash DividendMay 4, 2026 | prnewswire.comDominari 2025 Revenue Surges 487% in 2025, Balance Sheet Strengthens SignificantlyMarch 31, 2026 | prnewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 10 at 1:00 AM | Banyan Hill Publishing (Ad)Dominari Releases Letter to Shareholders and ClientsMarch 16, 2026 | prnewswire.comNew American Drone and Defense Company to be Created Through Merger of Powerus and Aureus Greenway HoldingsMarch 9, 2026 | globenewswire.comDominari Holdings Expands 2022 Equity Incentive Plan AuthorizationMarch 5, 2026 | tipranks.comSee More Dominari Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email. Email Address About DominariDominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.View Dominari ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/04 - 05/08Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major PlayersRocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance3 Under-The-Radar Small Caps Making New All-Time HighsFlutter Sees Post-Earnings Boost as FanDuel Shows Signs of RecoveryHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusWater Infrastructure: Why This Boring Sector Could Get Exciting Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
